HK1174056A1 - Pcsk9 vaccine pcsk9 - Google Patents

Pcsk9 vaccine pcsk9

Info

Publication number
HK1174056A1
HK1174056A1 HK13101001.0A HK13101001A HK1174056A1 HK 1174056 A1 HK1174056 A1 HK 1174056A1 HK 13101001 A HK13101001 A HK 13101001A HK 1174056 A1 HK1174056 A1 HK 1174056A1
Authority
HK
Hong Kong
Prior art keywords
pcsk9
vaccine
pcsk9 vaccine
vaccine pcsk9
Prior art date
Application number
HK13101001.0A
Other languages
English (en)
Chinese (zh)
Inventor
．錢皮恩
．小孔蒂洛
．艾森布勞恩
．弗雷澤
．霍金斯
．默森
．皮爾斯
．邱
．烏拉
．懷亞特
Original Assignee
輝瑞疫苗有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 輝瑞疫苗有限責任公司 filed Critical 輝瑞疫苗有限責任公司
Publication of HK1174056A1 publication Critical patent/HK1174056A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/005—Trypanosoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
HK13101001.0A 2009-09-03 2013-01-23 Pcsk9 vaccine pcsk9 HK1174056A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23954109P 2009-09-03 2009-09-03
PCT/IB2010/053784 WO2011027257A2 (en) 2009-09-03 2010-08-23 Pcsk9 vaccine

Publications (1)

Publication Number Publication Date
HK1174056A1 true HK1174056A1 (en) 2013-05-31

Family

ID=43413463

Family Applications (3)

Application Number Title Priority Date Filing Date
HK13101001.0A HK1174056A1 (en) 2009-09-03 2013-01-23 Pcsk9 vaccine pcsk9
HK15108893.4A HK1208346A1 (en) 2009-09-03 2015-09-11 Pcsk9 vaccine pcsk9
HK15110331.0A HK1209619A1 (en) 2009-09-03 2015-10-21 Pcsk9 vaccine pcsk9

Family Applications After (2)

Application Number Title Priority Date Filing Date
HK15108893.4A HK1208346A1 (en) 2009-09-03 2015-09-11 Pcsk9 vaccine pcsk9
HK15110331.0A HK1209619A1 (en) 2009-09-03 2015-10-21 Pcsk9 vaccine pcsk9

Country Status (30)

Country Link
US (4) US8889144B2 (es)
EP (3) EP2473605B1 (es)
JP (5) JP2013503623A (es)
KR (3) KR101660577B1 (es)
CN (3) CN104548089B (es)
AR (2) AR078247A1 (es)
AU (1) AU2010290931B2 (es)
BR (1) BR112012004807A2 (es)
CA (2) CA2846746A1 (es)
CO (1) CO6501190A2 (es)
DK (1) DK2473605T3 (es)
ES (1) ES2670576T3 (es)
HK (3) HK1174056A1 (es)
HU (1) HUE037416T2 (es)
IL (2) IL218229A (es)
MX (1) MX2012002639A (es)
MY (1) MY163512A (es)
NO (1) NO2473605T3 (es)
NZ (3) NZ599059A (es)
PE (3) PE20121544A1 (es)
PH (2) PH12016500004A1 (es)
PL (1) PL2473605T3 (es)
PT (1) PT2473605T (es)
RU (2) RU2538162C2 (es)
SA (3) SA114350178B1 (es)
SG (3) SG10201401515YA (es)
SI (1) SI2473605T1 (es)
TR (1) TR201808222T4 (es)
TW (1) TWI400085B (es)
WO (1) WO2011027257A2 (es)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2535898C2 (ru) * 2008-08-29 2014-12-20 Орал Хэлс Аустралиа Пти Лтд Профилактика, лечение и диагностика инфекции, вызванной бактериями p.gingivalis
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
AU2009325926B2 (en) 2008-12-09 2013-05-16 Coley Pharmaceutical Group, Inc. Immunostimulatory oligonucleotides
GB201005005D0 (en) * 2010-03-25 2010-05-12 Angeletti P Ist Richerche Bio New vaccine
WO2012131504A1 (en) * 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
EP2532359A1 (en) 2011-06-10 2012-12-12 Affiris AG CETP fragments
ES2565757T3 (es) * 2011-09-13 2016-04-06 Affiris Ag Vacuna de PCSK9
US9255154B2 (en) 2012-05-08 2016-02-09 Alderbio Holdings, Llc Anti-PCSK9 antibodies and use thereof
EP2703483A1 (en) 2012-08-29 2014-03-05 Affiris AG PCSK9 peptide vaccine
CA2888300A1 (en) * 2012-10-17 2014-04-24 Glaxosmithkline Biologicals S.A. Immunogenic composition
US10058630B2 (en) * 2012-10-22 2018-08-28 Concievalve, Llc Methods for inhibiting stenosis, obstruction, or calcification of a stented heart valve or bioprosthesis
US10117923B2 (en) 2012-11-07 2018-11-06 Vacplanta Limited Production of an immunogen using a plant virus
US20150274784A1 (en) * 2012-11-07 2015-10-01 Vacplanta Limted Production of an Immunogen Using a Plant Virus
TWI641382B (zh) * 2013-01-31 2018-11-21 韓美藥品股份有限公司 於包含因子ｖｉｉ之組成物中使病毒失活之方法
CN104043120B (zh) * 2013-03-13 2017-05-31 南京赛威信生物医药有限公司 乙型肝炎疫苗
EP3104877B1 (en) 2014-02-11 2020-01-22 The USA, as represented by The Secretary, Department of Health and Human Services Pcsk9 vaccine and methods of using the same
AU2015222283B2 (en) 2014-02-28 2019-11-21 Affiris Cvd Gmbh PCSK9 vaccines
CN104558199B (zh) * 2014-09-05 2018-07-06 成都康弘生物科技有限公司 一种治疗高胆固醇血症的融合蛋白制备及其用途
SI3325015T1 (sl) * 2015-07-20 2021-08-31 Zoetis Services Llc Liposomske pomožne sestavine
EP3365006A1 (en) 2015-10-19 2018-08-29 Cadila Healthcare Limited New adjuvant and vaccine composition containing the same
JP7378931B2 (ja) * 2015-11-03 2023-11-14 エイシー イミューン ソシエテ アノニム ヒト患者における自己抗原に対するワクチン接種法
EP4194007A1 (en) * 2016-03-25 2023-06-14 Osaka University Conjugate vaccine targeting disorder-causing in vivo protein
BR112018076242A2 (pt) * 2016-06-24 2019-03-26 Hoffmann La Roche inibidores de pcsk9, pcsk9 inibido, composição farmacêutica, métodos para modular a atividade de pcsk9, para inibir a ligação de pcsk9 a ldlr, para aumentar a disponibilidade de ldlr, para reduzir um nível de ldl-c, para reduzir o nível sérico de ldl-c, para o tratamento de um distúrbio relacionado com colesterol, métodos para o tratamento de um distúrbio associado a um nível anormal de ldl-c, de uma condição associada a um nível elevado de ldl-c, de dislipidemia, de hipercolesterolemia, usos de um inibidor de pcsk9 e método para identificar um composto candidato como um inibidor de pcsk9 que liga um epítopo da seq id nº 1
CN106822881A (zh) * 2016-12-09 2017-06-13 四川大学 一种针对pcsk9的抗高血脂蛋白疫苗
US11325945B2 (en) 2017-04-12 2022-05-10 Cadila Healthcare Limited Peptide based PCSK9 vaccine
CN107488215A (zh) * 2017-07-19 2017-12-19 邱志华 人前蛋白转化酶枯草溶菌素9免疫原性肽段及其载体疫苗
EP3993820A4 (en) * 2019-07-04 2023-08-16 Cadila Healthcare Limited VACCINE BASED ON ANGPTL3 FOR THE TREATMENT OF LIVER DISEASES
AU2021229710A1 (en) 2020-03-01 2022-10-06 Dynavax Technologies Corporation CPG-adjuvanted SARS-CoV-2 virus vaccine
WO2022147373A1 (en) * 2020-12-31 2022-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-guided pcsk9-mimicking immunogens lacking 9-residue sequence overlap with human proteins
WO2023161526A1 (en) 2022-02-28 2023-08-31 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773946A (en) 1969-09-02 1973-11-20 Parke Davis & Co Triglyceride-lowering compositions and methods
US3930024A (en) 1969-09-02 1975-12-30 Parke Davis & Co Pharmaceutical compositions and methods
JPS5522636A (en) 1978-08-04 1980-02-18 Takeda Chem Ind Ltd Thiazoliding derivative
WO1980000727A1 (en) 1978-09-29 1980-04-17 Secretary Energy Brit Improvements in and relating to electrical power transmission in fluid wells
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
AU548727B2 (en) 1981-03-12 1986-01-02 Gruppo Lepetit S.P.A. Beta-lactam acetic acid derivatives
DE3280400D1 (de) 1981-10-23 1992-06-04 Molecular Biosystems Inc Oligonukleotides heilmittel und dessen herstellungsverfahren.
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
IL64542A0 (en) 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
JPS60136512A (ja) 1983-12-26 1985-07-20 Eisai Co Ltd 脂質代謝改善剤
DE3423166A1 (de) 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
US4722840A (en) 1984-09-12 1988-02-02 Chiron Corporation Hybrid particle immunogens
US4709017A (en) 1985-06-07 1987-11-24 President And Fellows Of Harvard College Modified toxic vaccines
US5374426A (en) 1986-09-03 1994-12-20 University Of Saskatchewan Rotavirus nucleocapsid protein VP6 in vaccine compositions
US4950740A (en) 1987-03-17 1990-08-21 Cetus Corporation Recombinant diphtheria vaccines
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
ES2055785T3 (es) 1989-01-17 1994-09-01 Eniricerche Spa Peptidos sinteticos y su uso como vehiculos universales para la preparacion de conjugados inmunogenos aptos para el desarrollo de vacunas sinteticas.
HU212924B (en) 1989-05-25 1996-12-30 Chiron Corp Adjuvant formulation comprising a submicron oil droplet emulsion
US5334379A (en) 1989-07-14 1994-08-02 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
NZ235315A (en) 1989-09-19 1991-09-25 Wellcome Found Chimaeric hepadnavirus core antigen proteins and their construction
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
JP2999579B2 (ja) 1990-07-18 2000-01-17 武田薬品工業株式会社 Ｄｎａおよびその用途
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
AU9052091A (en) 1990-12-20 1992-07-22 Smithkline Beecham Biologicals (Sa) Vaccines based on hepatitis b surface antigen
DE4202394A1 (de) 1991-04-04 1992-10-08 Teves Gmbh Alfred Schwimmsattel-teilbelagscheibenbremse mit einem bremsengehaeuse aus leichtmetall
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
DE69324487T2 (de) 1992-05-06 1999-08-12 Harvard College Rezeptorbindende region des diphtherietoxius
RU2118164C1 (ru) 1992-06-25 1998-08-27 Смитклайн Бичам Байолоджикалс, С.А. Вакцинная композиция, обладающая свойством вызывать цитолитический т-клеточный ответ у млекопитающих, способ получения цитолитического т-клеточного ответа in vivo, способ получения вакцины
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US5917017A (en) 1994-06-08 1999-06-29 President And Fellows Of Harvard College Diphtheria toxin vaccines bearing a mutated R domain
US6455673B1 (en) 1994-06-08 2002-09-24 President And Fellows Of Harvard College Multi-mutant diphtheria toxin vaccines
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ES2366201T3 (es) 1994-07-15 2011-10-18 University Of Iowa Research Foundation Oligonucleótidos inmunmoduladores.
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US5648387A (en) 1995-03-24 1997-07-15 Warner-Lambert Company Carboxyalkylethers, formulations, and treatment of vascular diseases
WO1996030523A2 (en) 1995-03-31 1996-10-03 Hans Wolf Antigen presentation system based on retrovirus-like particles
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
GB9621091D0 (en) 1996-10-09 1996-11-27 Fondation Pour Le Perfectionem Attenuated microorganisms strains and their uses
ES2241042T3 (es) 1996-10-11 2005-10-16 The Regents Of The University Of California Conjugados de polinucleotido inmunoestimulador/ molecula inmunomoduladora.
IL119971A (en) 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
WO1998037919A1 (en) 1997-02-28 1998-09-03 University Of Iowa Research Foundation USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE IN THE TREATMENT OF LPS-ASSOCIATED DISORDERS
WO1998040100A1 (en) 1997-03-10 1998-09-17 Ottawa Civic Loeb Research Institute USE OF NUCLEIC ACIDS CONTAINING UNMETHYLATED CpG DINUCLEOTIDE AS AN ADJUVANT
ATE370740T1 (de) 1997-05-20 2007-09-15 Ottawa Health Research Inst Verfahren zur herstellung von nukleinsäurekonstrukten
ATE432348T1 (de) 1997-06-06 2009-06-15 Univ California Inhibitoren von immunstimulatorischen dna sequenz aktivität
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
IL121165A0 (en) 1997-06-26 1997-11-20 Yissum Res Dev Co Pharmaceutical compositions containing carboxylic acids and derivatives thereof
WO1999011241A1 (en) 1997-09-05 1999-03-11 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
CZ302092B6 (cs) 1998-02-12 2010-10-06 Immune Complex, Corporation Konjugát upraveného jaderného proteinu hepatitidy B, jeho cástice, inokulum a zpusob indukce protilátek
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
EP1067956B1 (en) 1998-04-03 2007-03-14 University Of Iowa Research Foundation Methods and products for stimulating the immune system using immunotherapeutic oligonucleotides and cytokines
PL354714A1 (en) 1998-04-09 2004-02-09 Smithkline Beecham Biologicals S.A. Adjuvant compositions
TWI227241B (en) * 1998-06-20 2005-02-01 United Biomedical Inc IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate
GB9817052D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Biolog Vaccine
WO2000017158A1 (de) 1998-09-18 2000-03-30 Pentapharm Ag Urokinase-inhibitoren
AU5728099A (en) 1998-09-28 2000-05-01 Hans Balle Aps Lift, preferably for seats on wheelchairs
US6203837B1 (en) 1998-10-06 2001-03-20 Xcafe' Llc Coffee system
EP1588714A2 (en) 1998-10-16 2005-10-26 GlaxoSmithKline Biologicals S.A. Adjuvant systems and vaccines
ES2258869T3 (es) 1998-10-21 2006-09-01 The United States Government As Represented By The Department Of Health And Human Services Particulas similares a virus para la induccion de autoanticuerpos.
AU775939B2 (en) 1998-11-05 2004-08-19 Powderject Vaccines, Inc. Nucleic acid constructs for genetic immunization
RU2245163C2 (ru) 1998-11-30 2005-01-27 Сайтос Байотекнолэджи АГ Композиция (варианты), способ получения не природной упорядоченной и содержащей повторы антигенной матрицы, способ терапевтического лечения и способ иммунизации
EP2050464B1 (en) 1998-12-21 2019-08-07 Medimmune, Inc. Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
HU229664B1 (en) 1998-12-23 2014-04-28 Id Biomedical Corp Quebec Streptococcus antigens
AUPP807399A0 (en) 1999-01-08 1999-02-04 Csl Limited Improved immunogenic lhrh composition and methods relating thereto
CA2362204C (en) 1999-02-17 2011-11-08 John Cooper Cox Immunogenic complexes and methods relating thereto
DE60032120T2 (de) 1999-03-19 2007-09-20 Glaxosmithkline Biologicals S.A. Impstoff gegen Streptococcus pneumoniae
ATE384035T1 (de) 1999-04-01 2008-02-15 Esperion Therapeutics Inc Ether-verbindungen, zusammensetzungen und ihre verwendung
JP2002541808A (ja) 1999-04-09 2002-12-10 テクラブ， インコーポレイテッド ポリサッカリド結合体ワクチンのための組換えトキシンａタンパク質キャリア
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
KR100922031B1 (ko) 1999-04-19 2009-10-19 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
NO309798B1 (no) * 1999-04-30 2001-04-02 Targovax As Peptidblanding, samt farmasoytisk sammensetning og kreftvaksine som innbefatter peptidblandingen
CA2383413A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Biologicals S.A. Use of combination of polyoxyethylene sorbitan ester and octoxynol as adjuvant and its use in vaccines
JP2003509452A (ja) 1999-09-24 2003-03-11 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ポリオキシエチレンアルキルエーテル又はエステル及び少なくとも一つのノニオン界面活性剤を含有するアジュバント
ATE333284T1 (de) 1999-09-27 2006-08-15 Coley Pharm Group Inc Verfahren mittels durch nukleinsäuren induziertes immunostimulatorisches interferon
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
US7270821B2 (en) 2000-04-07 2007-09-18 University Of Leeds Innovations Limited Hepatitis B core antigen fusion proteins
CA2407897A1 (en) 2000-05-05 2001-11-15 Cytos Biotechnology Ag Molecular antigen arrays and vaccines
EP1303612A2 (en) 2000-06-20 2003-04-23 Shire Biochem Inc. Streptococcus antigens
US20040054139A1 (en) 2000-06-22 2004-03-18 Mark Page Modification of hepatitis b core antigen
WO2002005690A1 (en) 2000-07-15 2002-01-24 Lighthouse Display International Limited Shelf edge display fittings
GB0121171D0 (en) * 2001-08-31 2001-10-24 Glaxosmithkline Biolog Sa Vaccine
AUPQ912000A0 (en) 2000-07-31 2000-08-24 Crown In The Right Of The Queensland Department Of Health, The Improved virus like particles
US20030138769A1 (en) 2000-08-16 2003-07-24 Birkett Ashley J. Immunogenic HBc chimer particles having enhanced stability
US7264810B2 (en) * 2001-01-19 2007-09-04 Cytos Biotechnology Ag Molecular antigen array
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
ATE447967T1 (de) * 2001-09-14 2009-11-15 Cytos Biotechnology Ag Verpackung von immunstimulierendem cpg in virusähnlichen partikeln: herstellungsverfahren und verwendung
EP1425040A2 (en) 2001-09-14 2004-06-09 Cytos Biotechnology AG In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
EP1432443B1 (en) 2001-10-05 2009-01-21 Cytos Biotechnology AG Angiotensin peptide-carrier conjugates and uses thereof
AU2002351623A1 (en) 2001-12-20 2003-07-09 Shire Biochem Inc. Streptococcus antigens
AU2003213168A1 (en) 2002-02-21 2003-12-19 Apovia, Inc. IMMUNOGENIC HBc CHIMER PARTICLES STABILIZED WITH AN N-TERMINAL CYSTEINE
GB0209878D0 (en) 2002-04-30 2002-06-05 Glaxosmithkline Biolog Sa Vaccine
CN1668637B (zh) 2002-07-17 2010-05-26 希托斯生物技术股份公司 使用衍生自ap205外壳蛋白的病毒样颗粒的分子抗原阵列
GB0219524D0 (en) * 2002-08-21 2002-10-02 Queen Mary & Westfield College Therapeutic uses of monoclonal antibodies to the angiotensin-II type-1 receptor
WO2004053091A2 (en) 2002-12-10 2004-06-24 Lorantis Ltd. STABILIZED IMMUNOGENIC HBc CHIMER PARTICLES
NZ541969A (en) 2003-03-13 2008-01-31 Glaxosmithkline Biolog Sa Purifying pneumolysin from Streptococcus pneumoniae in a single chromatographic step by binding it to a hydrophobic interaction column in the presence of detergent and high salt
EP1471152A1 (en) 2003-04-25 2004-10-27 Institut National De La Sante Et De La Recherche Medicale (Inserm) Mutations in the human PCSK9 gene associated to hypercholesterolemia
AU2005335104C1 (en) 2004-07-18 2010-10-28 Csl Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
AU2005333126A1 (en) 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing innate immune responses
GB0421083D0 (en) 2004-09-22 2004-10-27 Glaxosmithkline Biolog Sa Purification process
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
PT2405002E (pt) 2006-02-15 2015-01-05 Adiutide Pharmaceuticals Gmbh Composições e métodos para formulações de oligonucleotídeos
EP2021467A4 (en) * 2006-05-08 2010-01-20 Adaerata Ltd Partnership CHIMERIC PCSK9 PROTEINS, THESE INCLUDING CELLS AND TEST METHODS THEREWITH
US7572618B2 (en) * 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
US20080166785A1 (en) 2006-08-16 2008-07-10 Monica Sala-Schaeffer Polynucleotides allowing the expression and secretion of recombinant HBsAg virus-like particles containing a foreign peptide, their production and use
US8263353B2 (en) * 2007-03-27 2012-09-11 Merck Sharp & Dohme Corp. Method for detecting autoprocessed, secreted PCSK9
KR20100019440A (ko) * 2007-04-13 2010-02-18 노파르티스 아게 프로-단백질 전환효소 서브틸리신/켁신 유형 ９ (ｐｃｓｋ９)를 조정하기 위한 분자 및 방법
DK2167121T3 (en) 2007-06-26 2015-11-23 Glaxosmithkline Biolog Sa A vaccine comprising Streptococcus pneumoniae kapselpolysaccharidkonjugater
JOP20080381B1 (ar) * 2007-08-23 2023-03-28 Amgen Inc بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9)
MX2010004454A (es) * 2007-10-26 2010-07-28 Schering Corp Anti-proproteina convertasa subtilisina/kexina tipo 9 y metodos para tratar trastornos de lipidos y colesterol.
AU2008339904A1 (en) * 2007-12-20 2009-07-02 Cytos Biotechnology Ag Nerve growth factor conjugates and uses thereof
AR070315A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Anticuerpos 1b20 antagonistas de pcsk9
AR070316A1 (es) 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
TWI516501B (zh) * 2008-09-12 2016-01-11 禮納特神經系統科學公司 Ｐｃｓｋ９拮抗劑類
AT507604A1 (de) 2008-11-19 2010-06-15 Affiris Forschungs & Entwicklungs Gmbh Behandlung von atherosklerose
US9501570B2 (en) 2014-07-14 2016-11-22 Verizon Patent And Licensing Inc. Dynamic routing system
US9719791B2 (en) 2014-12-10 2017-08-01 Mapquest, Inc. Computerized systems and methods for providing travel information and/or content to users
US10114918B2 (en) 2016-01-27 2018-10-30 Arm Limited Physical placement control for an integrated circuit based on state bounds file
EP3928994A1 (en) 2016-06-23 2021-12-29 Ripples Ltd. Printing on a drink in accordance with a container property

Also Published As

Publication number Publication date
AR107020A2 (es) 2018-03-14
PH12016500040A1 (en) 2016-12-05
US8889144B2 (en) 2014-11-18
US20110052621A1 (en) 2011-03-03
TW201113035A (en) 2011-04-16
HK1209619A1 (en) 2016-04-08
AR078247A1 (es) 2011-10-26
CA2771770A1 (en) 2011-03-10
TWI400085B (zh) 2013-07-01
SA114350179B1 (ar) 2016-03-01
RU2538162C2 (ru) 2015-01-10
JP5859150B2 (ja) 2016-02-10
EP2865752A1 (en) 2015-04-29
KR20140004263A (ko) 2014-01-10
EP3358008A1 (en) 2018-08-08
IL254600A0 (en) 2017-11-30
NZ710626A (en) 2017-03-31
WO2011027257A2 (en) 2011-03-10
MY163512A (en) 2017-09-15
SG178447A1 (en) 2012-03-29
IL218229A (en) 2017-10-31
JP2015131814A (ja) 2015-07-23
PH12016500004A1 (en) 2016-12-05
SI2473605T1 (en) 2018-06-29
ES2670576T3 (es) 2018-05-31
RU2012107657A (ru) 2013-10-10
PT2473605T (pt) 2018-05-28
CN104587462A (zh) 2015-05-06
NZ599059A (en) 2014-05-30
DK2473605T3 (en) 2018-05-28
KR101512053B1 (ko) 2015-04-28
KR101660577B1 (ko) 2016-09-27
AU2010290931A1 (en) 2012-03-29
CN102612558B (zh) 2015-02-11
RU2014143531A (ru) 2016-05-20
PE20161560A1 (es) 2017-01-11
KR20140007500A (ko) 2014-01-17
SG10201401516XA (en) 2014-10-30
PE20121544A1 (es) 2012-12-02
HUE037416T2 (hu) 2018-08-28
NO2473605T3 (es) 2018-09-08
US9987341B2 (en) 2018-06-05
AU2010290931B2 (en) 2014-02-06
EP2473605B1 (en) 2018-04-11
SA114350178B1 (ar) 2017-03-05
CN104548089B (zh) 2017-09-26
JP2016106089A (ja) 2016-06-16
US9481875B2 (en) 2016-11-01
PE20161551A1 (es) 2017-01-18
RU2014143531A3 (es) 2018-06-22
CA2846746A1 (en) 2011-03-10
CO6501190A2 (es) 2012-08-15
IL218229A0 (en) 2012-04-30
SG10201401515YA (en) 2014-08-28
US20180318407A1 (en) 2018-11-08
PL2473605T3 (pl) 2018-08-31
CN104548089A (zh) 2015-04-29
TR201808222T4 (tr) 2018-07-23
US20170100467A1 (en) 2017-04-13
EP2473605A2 (en) 2012-07-11
HK1208346A1 (en) 2016-03-04
KR101660578B1 (ko) 2016-09-27
BR112012004807A2 (pt) 2017-04-11
JP2013503623A (ja) 2013-02-04
CN102612558A (zh) 2012-07-25
JP2017039748A (ja) 2017-02-23
KR20120089451A (ko) 2012-08-10
NZ620441A (en) 2015-08-28
SA110310687B1 (ar) 2014-10-16
MX2012002639A (es) 2012-03-14
US20150098957A1 (en) 2015-04-09
CN104587462B (zh) 2017-09-26
JP2018039821A (ja) 2018-03-15
WO2011027257A3 (en) 2011-06-30

Similar Documents

Publication Publication Date Title
IL254600A0 (en) pcsk9 vaccine
IL217008A0 (en) Vaccine
GB0905570D0 (en) Combined vaccines
IL211233A0 (en) Vaccine
HRP20151124T1 (en) Vaccine
EP2408473A4 (en) METHODS OF VACCINATION
GB0822001D0 (en) Vaccine
GB201006165D0 (en) Vaccine
GB0810710D0 (en) Vaccine
IL208652A0 (en) Vaccine
GB0907935D0 (en) Vaccines
GB0816284D0 (en) Vaccine
IL216102A0 (en) Combined measles-malaria vaccine
GB0816447D0 (en) Vaccine
GB201000522D0 (en) Vaccine
IL217194A0 (en) Vaccine
GB0914545D0 (en) Vaccine
ZA201107971B (en) Combined measles-malaria vaccine
GB0909146D0 (en) Vaccines
GB0909145D0 (en) Vaccines
GB0909144D0 (en) Vaccines
GB0909147D0 (en) Vaccines
GB0810914D0 (en) Vaccine
AU2008267307A1 (en) Vaccine
AP2010005295A0 (en) Vaccine

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190826